Why is BRVE up?
Up 7% on Nov 11, an up day for the market: the S&P 500 rose 1%, 62% of stocks rose, and biotech stocks a median 0.9%.
- Its Nov 10 results:
BRVE's Quality Score fell 1 point on Fri, Nov 20, to 1. It closed away from its high of the day.
New listing, trading since Aug 6, 2026. 76 trading days so far, so 3 of the 14 chart checks wait for more history.
Follow BRVE's trial news. Pro members can get an alert when Braveheart Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 7% on Nov 11, an up day for the market: the S&P 500 rose 1%, 62% of stocks rose, and biotech stocks a median 0.9%.
| Holding it back | Moves 8.1% a day with no profit behind it |
| Latest filing | 8-K, Nov 10 |
After its last 2 reports it closed +2.4% on average, higher 1 of 2 times.
$504M in cash
No shelf registration or at-the-market program on file in the last three years.
Director Erez Chimovits bought 1,940,000 shares on Aug 7. 7 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
BRVE is #89 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 89 |
Expected to report Thu Mar 18, after the close (in 117 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.51 a share, from $10.05.
“The increase was primarily due to clinical and manufacturing costs to support the initiation and enrollment of LIONHEART-HCM, higher personnel-related costs and a $1.0 million milestone under the Hengrui license agreement.”
BRVE's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to personnel-related costs, including stock-based compensation, and consultant and legal costs to support Braveheart Bio's growth and operations as a public company.”
From its results filing (SEC filing · Nov 10)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 10, 2026 | +2.1% | +6.5% | -4.3% |
| Sep 8, 2026 | -0.9% | -1.7% | -9.2% |
RSI 50.7, MACD above signal. Not scored.
Officers and directors with a Form 4 in the last 12 months.
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Listed on Nasdaq on Aug 6, 2026, and is 13% above its $18 offer price now. Its IPO filing and first days
BRVE scores 1 today, which Breakaway calls Below Average. It is #89 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 7% on Nov 11, an up day for the market: the S&P 500 rose 1%, 62% of stocks rose, and biotech stocks a median 0.9%. Shares: 8.9 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BRVE scores 1 today, which Breakaway calls Below Average (0 to 5). That is #89 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BRVE's 1.
Expected to report Thu Mar 18, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BRVE closed higher after 1 of its last 2 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.